Subcutaneous Remsima non-inferior to IV formulation

The intravenous and subcutaneous formulations of Remsima had comparable efficacy, safety and immunogenicity profiles in patients with inflammatory bowel disease, according to study results.Byong Duk Ye, MD, PhD, from the department of gastroenterology and IBD center at University of Ulsan College of Medicine in South Korea, and colleagues wrote that the IV formulation of Remsima (CT-P13 IV, Celltrion) has an established role in the treatment of IBD, but a subcutaneous version (CT-P13 SC) has several potential benefits.“Subcutaneous biologics may benefit IBD patients, including throughRead More

Share on facebook
Share on twitter
Share on linkedin